Brainomix, an Oxford-based medical diagnostics software company, has secured £16m ($21.2m) funding to make its AI-powered stroke imaging solution capable of diagnosing other diseases such as lung fibrosis and cancer.

The latest funding will enable Brainomix to expand into new markets, as well as adapt its software to look for other therapeutic indicators. Founded in 2010 by Andrew Barker and Michalis Papadakis , Brainomix has developed an AI-powered imaging tool for detecting biomarkers – medical characteristics that indicate a specific disease – to improve both diagnosis and treatment decisions. Brainomix has a robust track record of delivering innovative AI solutions and is committed to positively impacting treatment rates and patient outcomes.

Oxford Medtech Brainomix Raises £16M To Expand Ai Tool Beyond Stroke Diagnosis

Description

Company Information

Funding Insights

Oxford Medtech Brainomix Raises £16M To Expand Ai Tool Beyond Stroke Diagnosis

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Funding Insights

Company Information